Effect of Herceptin combined with paclitaxel neoadjuvant chemotherapy on the proliferation viability of HER-2 positive breast cancer cell

摘要

Objective: To study the effect of Herceptin combined with paclitaxel neoadjuvant chemotherapy on the proliferation viability of HER-2 positive breast cancer cell. Methods:The patients who were diagnosed with breast cancer and received neoadjuvant chemotherapy in Ziyang First People's Hospital between February 2015 and October 2017 were selected and randomly divided into the experimental group who received Herceptin combined with docetaxel chemotherapy and the control group who received epirubicin combined with docetaxel chemotherapy. After chemotherapy ended, serum levels of tumor markers were measured; after surgical resection, the breast cancer lesions were collected to measure the mRNA expression of proliferation genes and tumor suppressor genes. Results: The differences in tumor marker levels as well as proliferation gene and tumor suppressor gene expression were statistically significant between the two groups; CA15-3, IGF-1, TSGF and TPS levels in serum as well as CyclinD1, PCNA, Bcl-2, Survivin and VEGF mRNA expression in breast cancer lesions of experimental group were lower than those of control group whereas PTEN, Bax, ARID1A, FasL and Caspase-3 mRNA expression in breast cancer lesions were higher than those of control group. Conclusion: Herceptin combined with paclitaxel neoadjuvant chemotherapy can more effectively inhibit the proliferation activity of HER-2 positive breast cancer cells than epirubicin combined with paclitaxel chemotherapy.